DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/vh6xvv/investigation) has announced the addition of the "Investigation Report on China's Leuprorelin Market, 2010-2019" report to their offering.
Originally developed by Takeda Pharmaceutical Co., Ltd, leuprorelin is a polypeptide used to treat prostate cancer. Leuprorelin can inhibit the pituitary gland and released gonadotropin Leuprolide acts as an agonist at pituitary GnRH receptors, leading to hypogonadism and thus a dramatic reduction in estradiol and testosterone levels in both sexes.
Having been marketed in 1994 for the first time, leuprorelin entered China under the trade name of enantone in 2000. As it is the specific drug for such sex hormone-related diseases as prostate cancer and endometriosis, it grew fast in China. Due to the technology involved in production of polypeptide, there was no generic drug for a long time despite its lack of patent protection in China. Currently, only generic drugs of Beijing Biote and Livzon are approved.
Leuprorelin developed fast after entering China with sales value in sample hospitals rising from about CNY 20 million in 2005 to over CNY 260 million in 2014 and CAGR during the period of 2006- 2010 reaching 37%. Leuprorelin enjoys a vast demand in China. And Livzon, Beijing Biote Pharmaceutical Co., Ltd and Takeda Pharmaceutical Co., Ltd (Japan) occupies the market, among which Takeda Pharmaceutical Co., Ltd (Japan) had the largest market share of nearly 60% for sales value in 2014.
Due to unreliable dietary requirements, Chinese children report increasingly obvious symptoms of sexual precocity, which is bad for their healthy development and attracts more and more parents' attention. In recent years, such problems as female fibroids caused by abnormal secretion of hypophyseal hormones have become increasingly prominent. As these problems are increasingly emphasized, leuprorelin which regulates the secretion of gonadotropins will enjoy a vast market. Since Lee's Pharmaceutical Holdings Limited is now the only company which applied to produce generic drugs of leuprorelin, there are still opportunities for future generic drugs.
Key Topics Covered:
1 Related Concepts of Leuprorelin
2 Market Profile of Leuprorelin in China
3 Survey on Leuprorelin Sales in China, 2010-2014
4 Survey on Market Share of Major Leuprorelin Manufacturers in China, 2010-2014
5 Survey on Dosage Forms of Leuprorelin in China, 2010-2014
6 Reference Price of Leuprorelin in Chinese Hospitals in 2014
7 Major Manufacturers of Leuprorelin in Chinese Market
8 Market Outlook of Leuprorelin in China, 2015-2019
- Beijing Biote Pharmaceutical Co., Ltd
- Shanghai Livzon Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/vh6xvv/investigation